GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Eisen(III)natrium-Gluconat-Komplex (B03AC07) im Rahmen eines sogenannten Open-House-Modells.

Health · Germany government procurement

Closed September 30, 2026. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of non-exclusive discount agreements pursuant to Sections 130a para. 8/130c para. 1 SGB V for medicinal products containing the active ingredient iron(III) sodium gluconate complex (B03AC07) within the framework of a so-called open-house model.

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedOctober 11, 2024
Procurement stageActive solicitation
ClosedSeptember 30, 2026
StatusClosed — no longer accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 12, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Browse Similar Open Opportunities in Germany

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Lapatinib, ATC L01EH01
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Kaliumiodid, ATC H03CA01 für die Zeit 01.03.2026 - 29.02.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Kontrastmittel - Wirkstoffübergreifendes Open-House-Verfahren für die KV-Region Rheinland-Pfalz/Saarland
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tapentadol in den nicht retardierten Darreichungsformen, ATC N02AX06
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Relugolix (ATC-Code: L02BX04).
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Testosteron in der Darreichungsform Injektionslösung, ATC G03BA03
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.09.2025
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Erythropoietin (ATC-Code B03XA01).

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.